Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
Neuphoria Therapeutics Inc. has successfully completed its re-domiciliation from Australia to the U.S., becoming the parent company of Bionomics Limited. The company's shares will begin trading on Nasdaq under the symbol "NEUP" on December 24, 2024. Neuphoria will also issue options and warrants to existing Bionomics option holders and an institutional investor, respectively. Neuphoria focuses on developing therapies for neuropsychiatric disorders, including its lead candidate BNC210 for social anxiety disorder and PTSD.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments